MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Bluebird Bio Inc

Closed

4.92 -5.02

Overview

Share price change

24h

Current

Min

4.79

Max

5.35

Key metrics

By Trading Economics

Income

32M

-29M

Sales

28M

39M

EPS

-2.84

Profit margin

-74.536

Employees

248

EBITDA

20M

-40M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+29.22% upside

Market Stats

By TradingEconomics

Market Cap

9.6M

48M

Previous open

9.94

Previous close

4.92

Technical Score

By Trading Central

Confidence

Bullish Evidence

Bluebird Bio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2024, 16:08 UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

Peer Comparison

Price change

Bluebird Bio Inc Forecast

Price Target

By TipRanks

29.22% upside

12 Months Forecast

Average 6.5 USD  29.22%

High 8 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forBluebird Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

3.72 / 3.82Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

No Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.